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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease involving the formation of cytoplasmic
aggregates by proteins including TDP-43 and SOD1, in affected cells in the central nervous system (CNS).
Pathology spreads from an initial site of onset to contiguous anatomical regions. There is evidence that for
disease-associated proteins, including TDP-43 and SOD1, non-native protein conformers can promote
misfolding of the natively folded counterparts, and cell-to-cell transfer of pathological aggregates may underlie
the spread of the disease throughout the CNS. A variety of studies have demonstrated that SOD1 is released
by neuron-like cells into the surrounding culture medium, either in their free state or encapsulated in
extracellular vesicles such as exosomes. Extracellular SOD1 can then be internalised by naïve cells incubated
in this conditioned medium, leading to the misfolding and aggregation of endogenous intracellular SOD1; an
effect that propagates over serial passages. A similar phenomenon has also been observed with other proteins
associated with protein misfolding and progressive neurological disorders, including tau, α-synuclein and both
mammalian and yeast prions. Conditioned media experiments using TDP-43 have been less conclusive, with
evidence for this protein undergoing intercellular transfer being less straightforward. In this review, we
describe the properties of TDP-43 and SOD1 and look at the evidence for their respective abilities to
participate in cell-to-cell transfer via conditioned medium, and discuss how variations in the nature of cell-to-
cell transfer suggests that a number of different mechanisms are involved in the spreading of pathology in ALS.
Disciplines
Medicine and Health Sciences
Publication Details
Hanspal, M. A., Dobson, C. M., Yerbury, J. J. & Kumita, J. R. (2017). The relevance of contact-independent
cell-to-cell transfer of TDP-43 and SOD1 in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta -
Molecular Basis of Disease, 1863 (11), 2762-2771.
This journal article is available at Research Online: http://ro.uow.edu.au/ihmri/1127
Contents lists available at ScienceDirect
BBA - Molecular Basis of Disease
journal homepage: www.elsevier.com/locate/bbadis
Review
The relevance of contact-independent cell-to-cell transfer of TDP-43 and
SOD1 in amyotrophic lateral sclerosis
Maya A. Hanspala, Christopher M. Dobsona, Justin J. Yerburyb,⁎, Janet R. Kumitaa,⁎
a Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK
b Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, NSW 2522, Australia







A B S T R A C T
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease involving the formation of cytoplasmic ag-
gregates by proteins including TDP-43 and SOD1, in affected cells in the central nervous system (CNS).
Pathology spreads from an initial site of onset to contiguous anatomical regions. There is evidence that for
disease-associated proteins, including TDP-43 and SOD1, non-native protein conformers can promote misfolding
of the natively folded counterparts, and cell-to-cell transfer of pathological aggregates may underlie the spread
of the disease throughout the CNS. A variety of studies have demonstrated that SOD1 is released by neuron-like
cells into the surrounding culture medium, either in their free state or encapsulated in extracellular vesicles such
as exosomes. Extracellular SOD1 can then be internalised by naïve cells incubated in this conditioned medium,
leading to the misfolding and aggregation of endogenous intracellular SOD1; an effect that propagates over serial
passages. A similar phenomenon has also been observed with other proteins associated with protein misfolding
and progressive neurological disorders, including tau, α-synuclein and both mammalian and yeast prions.
Conditioned media experiments using TDP-43 have been less conclusive, with evidence for this protein un-
dergoing intercellular transfer being less straightforward. In this review, we describe the properties of TDP-43
and SOD1 and look at the evidence for their respective abilities to participate in cell-to-cell transfer via con-
ditioned medium, and discuss how variations in the nature of cell-to-cell transfer suggests that a number of
different mechanisms are involved in the spreading of pathology in ALS.
1. Amyotrophic lateral sclerosis and protein misfolding
Amyotrophic lateral sclerosis (ALS), the most common form of
motor neurone disease (MND), is a rapidly progressive neurodegen-
erative condition caused by the loss of upper (UMN) and lower motor
neurons (LMN) in the central nervous system (CNS). This neuronal loss
results in a range of symptoms that may include muscle weakness and
wasting, limb rigidity and difficulty in swallowing, speaking and
breathing, culminating in paralysis and eventually death. Symptoms
usually present at a focal site of onset, often an upper or lower limb,
before spreading to contiguous neuroanatomical regions [1,2]. The
extension of clinical symptoms is accompanied by the spatiotemporal
progression of pathology throughout the CNS [3–6], which is char-
acterised by the deposition of aggregated proteins in affected cells.
Familial ALS (fALS) accounts for approximately 10% of all cases of the
disease, with the other 90% being sporadic (sALS); however, there is no
evident difference in clinical presentation between sALS and fALS pa-
tients, suggesting that a common molecular mechanism underlies the
disease. Misfolded Tar DNA-binding protein 43 (TDP-43) is the major
component of the inclusions found by autopsy in the majority of both
sALS and fALS patients, although in a small fraction of cases the in-
clusions primarily contain the proteins copper-zinc superoxide dis-
mutase 1 (SOD1) or fused in sarcoma/translocated in liposarcoma
(FUS) [7].
1.1. TDP-43
TDP-43 is a protein containing 414 amino acid residues and is en-
coded by the TARDBP gene. It belongs to a family of RNA binding
proteins known as heterogeneous nuclear ribonucleoproteins (hnRNPs),
but, unlike most members of this family, TDP-43 forms a homodimer
even in the absence of RNA [8,9]. It has a range of physiological roles
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involving the control of transcription and translation, including splicing
and the regulation of non-coding RNA [10]. TDP-43 regulates its own
mRNA levels through binding to the 3’UTR of the TDP-43 transcript,
such that high levels of protein downregulate endogenous TDP-43 ex-
pression via a negative feedback loop. Only one ALS-associated muta-
tion, occurring in a region potentially important for RNA binding, has
been found to interfere with this feedback loop [11]. It is possible,
however, that TDP-43 aggregates could also disrupt this process by
sequestering functional protein, thus removing regulatory control over
TDP-43 production [11].
The accumulation of aggregated and post-translationally modified
TDP-43 is considered a biochemical signature of ALS, and may play a
significant role in driving pathogenesis. It was first identified as a
component of inclusions in both sALS and frontotemporal lobar de-
mentia (FTLD) by two different groups in 2006, having previously been
known to bind a motif in the HIV transactive response DNA, and to
participate in a complex involved in the splicing of the cystic fibrosis
transmembrane conductance regulator (CFTR) gene [12–14]. Since
then, much work has been done to investigate the way in which TDP-43
contributes to the onset and progression of ALS. Over 50 disease-asso-
ciated mutations have been identified [10,15], the majority being lo-
cated within an aggregation-prone region of the protein and appearing
to enhance its aggregation propensity [16]. Under normal conditions
TDP-43 is predominantly a nuclear protein, but in ALS and FTLD there
is a loss of functional TDP-43 which results in detrimental effects on
RNA metabolism, in combination with the cytosolic accumulation of
aggregates that leads to neurotoxicity [17,18]. TDP-43 aggregation
culminates in the deposition of both round and skein-like cytoplasmic
inclusions, often associated with depletion of the protein from the nu-
cleus [13,14].
TDP-43 contains two RNA recognition motifs (RRM1 and RRM2),
which interact with nucleic acids, as well as a glycine-rich C-terminus.
RRM1 is responsible for preferential binding of TDP-43 to UG-repeated
motifs in RNA [19]. Almost all ALS-associated mutations in TDP-43
occur in the C-terminus within the glycine-rich domain, strongly sug-
gesting that the function of this domain is important in neurodegen-
eration [20]. The C-terminus not only mediates protein-protein inter-
actions but also contains a region rich in glutamine (Q) and arginine (N)
residues (Q/N rich region), which confers properties similar to those of
yeast prions [21]. The similarity in sequence between the Q/N-rich
region and yeast prion domains may relate to its cellular function, as
when the prion-like domain within the C-terminus of full-length TDP-43
tagged with GFP was replaced with the yeast prion domain of Sup35 in
transfected cells, in vivo splicing assays showed that this construct
regulated exon 9 skipping of the (CFTR) gene in the same way as WT
TDP-43 does [16]. This observation suggests that the Q/N-rich region
may have a functional role under normal conditions and only adopts an
aggregation-prone conformation after a disease-triggering event [21].
The general consensus, based on a number of studies designed to pin-
point the key sequences for aggregation, suggest the critical sequence
for aggregation is located between residues 286–353 [22], although
there is evidence that the truncated C-terminal RRM2 domain
(208–265) drives formation of non-amyloid fibrils, as confirmed by the
amyloid detecting dye Thioflavin T (ThT), in vitro and in vivo [9]. While
aggregates formed from C-terminal fragments or the full-length protein
do not react with Congo Red, another dye used to confirm that ag-
gregates are amyloid [23], two recent studies have found that the
fluorescent dye Thioflavin-S, that also binds to amyloid species, binds
to TDP-43 positive skein-like inclusions in a subset of ALS cases, sug-
gesting that pathological TDP-43 aggregates may in fact have amyloi-
dogenic properties [24,25]. Studies using ALS patient brain lysate
containing pathogenic TDP-43 have shown that this material can seed
the formation of insoluble TDP-43 inclusions in cell cultures, and this
can propagate between cells over serial passages [26,27].
1.2. SOD1
The gene that encodes copper-zinc superoxide dismutase 1 (SOD1)
was first associated with ALS in 1993, with mutations in this gene ac-
counting for 20% of fALS cases [28,29]. Its canonical role is as a free
radical scavenger, but there is emerging evidence that it may also act as
a transcription factor [30] and an RNA binding protein [31]. It is highly
stable in its native state, but may misfold in response to a variety of
triggers, including oxidative stress. Nearly 200 disease-causative mu-
tations have been identified throughout the sequence, all of which
appear to converge on the exposure of hydrophobic surfaces that are
normally buried within the molecule when natively folded [32]. Mis-
folding of SOD1 results in a gain of function effect, with the presence of
aggregates leading to cell death, and SOD1-ALS pathology is char-
acterised by the deposition of conglomerate inclusions enriched in
SOD1 that are normally negatively immunoreactive for TDP-43 [33].
Eukaryotic WT SOD1 exists as a stable 32 kDa homodimer pre-
dominantly located in the cytoplasm, although it can also be found in
the nucleus [34]. The homodimer adopts an eight-stranded Greek key
β-barrel structure stabilised by an intra-subunit disulphide bond, and
each subunit binds one copper atom and one zinc ion. These post-
translational modifications all contribute to the stability of SOD1,
making it exceptionally resistant to heat denaturation, and conferring
the ability to retain function under denaturing conditions [35,36].
It is thought that immature and unfolded SOD1, in a disulphide-
reduced state that does not bind zinc or copper ions, is responsible for
aggregation in vivo, although identifying the structure of the species
involved is challenging due to the conformational heterogeneity of its
non-native state. ALS-associated mutations, as well as aberrant post-
translational modifications to the WT protein, destabilise SOD1 and
cause it to misfold [37]. It is currently unclear whether or not amyloid
fibrils are important in SOD1 mediated ALS, as SOD1 positive inclusions
from ALS patient tissue do not show Thioflavin-S or Congo Red binding
[23]. SOD1 does, however, bind to ThT during in vitro aggregation
assays [38]. Furthermore, computational modelling has identified
amyloidogenic segments within the molecule that can be used to pro-
duce synthetic peptides that aggregate into structures with fibrillar
morphology when imaged using transmission electron microscopy [39].
In vitro aggregation studies have been carried out with WT SOD1
and several mutational variants, under a range of different conditions to
characterise the different types of aggregate species. Initial experiments
used the apo WT SOD1 variant where the cysteine residues at positions
6 and 11 were substituted by alanine and serine respectively (apo AS-
WT SOD1) and showed this protein has similarities to WT SOD1 in
terms of structure, stability and metal binding. It was found to be
possible to form fibrils from soluble apo AS-WT SOD1 at pH 3.5 in the
presence of EDTA over a period of months and electron microscopy
showed aggregates of mixed morphology including fibrils [40]. These
conditions, however, are not close to physiological, and so further work
has been done to explore aggregation under conditions more likely to
be encountered inside a cell. Apo SOD1 containing an N-terminal His6
tag and where cysteine 6 and 11 were both mutated to serine (SS-SOD1)
was observed to form insoluble amyloid fibrils at pH 7 and apo SOD1
where all four cysteines are reduced, thereby lacking the disulphide
bond, was observed to form aggregates in physiological buffer condi-
tions at 37 °C with agitation overnight. These aggregates exhibit amy-
loid properties when analysed using a range of biophysical techniques
and the fibrils were also found to seed the aggregation of soluble SOD1
[41]. Apo WT human SOD1 recombinantly expressed in yeast, thereby
retaining all post-translational modifications occurring in vivo, has also
been studied and observed to form fibrillar species under mild reducing
conditions. It was also found that the presence of a small amount of
disulphide reduced apo WT SOD1 was sufficient to induce fibril for-
mation of apo WT SOD1, suggesting that destabilisation of the homo-
dimer produces monomeric SOD1 nuclei that recruits apo WT SOD1
into the fibrils, providing a role for WT SOD1 in the disease process
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[42].
Different SOD1 mutational variants have previously been observed
to have a variety of aggregation propensities when expressed in cul-
tured cells, enabling the behaviour of recombinant SOD1 variants in
vitro to be compared to their intracellular aggregation [37]. Using
motor-neuron like NSC-34 cells expressing different SOD1 variants
tagged with eGFP, it was possible to quantify the number of aggregates
present 48 h post-transfection. By plotting the end point ThT fluores-
cence versus the percentage of cells showing inclusions for each variant,
it was evident that the aggregation propensity of SOD1 in vitro can
predict its aggregation propensity in cells. Interestingly, the strongest
correlation was between the in vitro aggregation propensity for specific
variants and patient disease duration, which could be used to predict
disease severity. It appears that the aggregation kinetics governing in
vitro fibril formation and aggregation in mouse models are very similar,
although this does not directly translate to human disease [43].
Nevertheless, these strategies have provided a great deal of information
regarding the folding and aggregation of SOD1 in disease.
SOD1 also participates in the cell-to-cell propagation of aggregates
over serial passages [44,45], suggesting that protein aggregation re-
presents an important and common pathogenic mechanism. Many
mutations in genes encoding proteins other than TDP-43 and SOD1
have since been discovered, but histopathology mainly converges on
the deposition of misfolded TDP-43, and in some cases, SOD1 or FUS,
regardless of the initial cause of the disease [29].
1.3. Other molecular players in ALS and FTLD: FUS, C9orf72 and tau
FUS is another RNA binding protein that is normally found in the
nucleus but shows enhanced aggregation propensity as a result of ALS-
associated mutations, and is deposited in cytoplasmic inclusions in a
small subset of both sALS and fALS cases (for review see [46]). One
study has demonstrated that a mutational variant of FUS can seed the
aggregation of WT FUS both in vitro and in vivo; however, there is
currently no experimental evidence of cell-to-cell transfer of FUS ag-
gregates in a similar manner to those of TDP-43 and SOD1 [47].
A major discovery was made in 2011, when genomic sequencing
revealed a noncoding GGGGCC nucleotide repeat expansion in the first
intron of gene C9orf72 as the most common cause of familial ALS and
FTLD, as well as accounting for a considerable proportion of sporadic
cases [48,49]. While the presence of fewer than 30 repeats is now as-
sociated with disease, in affected patients this can reach up to hundreds
or even thousands of repeats, although there is no clear relationship
between the size of the nucleotide repeat expansion and either disease
severity or age of onset [50]. Putative mechanisms of neurotoxicity
include: loss of functional C9orf72 protein, production of toxic RNA foci
and accumulation of different dipeptide repeats encoded by the hex-
anucleotide repeat expansions (for review see [50]), all of which are
capable of disrupting normal cellular function. Very recently it was
shown that these dipeptide repeat proteins can undergo cell-to-cell
transfer through direct intercellular contact as well as exosome de-
pendent mechanisms [51].
No mutations in the MAPT gene encoding the microtubule-asso-
ciated protein tau have so far been associated with ALS, but there ap-
pears to be an overlap in histopathology between hyperphosphorylated
tau and TDP-43 in some cases of ALS with cognitive impairment, al-
though the significance of this is unclear [52]. Tau pathology is more
commonly found in diseases including Alzheimer's disease and a subset
of FTLD, collectively termed as tauopathies. Transfer of aggregated tau
between cells has been demonstrated in several studies (for review see
[53]), and there is evidence that different tau strains exist that are
capable of serially propagating their distinct structural properties in
both cell lines and in mice.
1.4. Protein misfolding and aggregation in disease
Protein misfolding and aggregation has been implicated in a number
of increasingly prevalent human diseases ranging from neurodegen-
eration to diabetes [54]. The ability of a normally soluble peptide or
protein to aggregate into ordered fibrils has been discovered to be a
generic property of polypeptide chains, although aggregation pro-
pensity is, in part, encoded in the amino acid sequence [55]. Persistent
protein misfolding in vivo arises either from natively folded proteins
adopting an alternative conformation or through incorrect folding
during synthesis [56]. This is a comparatively rare event as there are
cellular strategies in place either to refold the protein into a functional
structure or to degrade misfolded conformers. Partially folded or mis-
folded proteins, however, pose a problem because they are at greater
risk of aberrant interactions with other molecules. This is because hy-
drophobic regions of the protein that are normally buried within the
core of the molecule become exposed to the aqueous environment and
can self-associate through hydrophobic interactions and hydrogen
bonding, thereby losing solubility associated with the native state [54].
Protein aggregates can adopt a variety of stable structures including
amorphous assemblies, oligomeric species and amyloid fibrils. The
latter species are of particular interest because they are highly struc-
tured self-associated protein multimers with characteristic physico-
chemical properties.
Despite the number of proteins linked with misfolding diseases,
there are no common features of their primary sequences or their sec-
ondary or tertiary structures [54]. Amyloid fibrils themselves share a
remarkably similar structural nature, forming closely packed structures
rich in β-sheet content. They form long thread-like filamentous struc-
tures that are approximately 10 nm in diameter, but can reach micro-
meters in length, with mature fibrils consisting of intertwining proto-
fibrils. Their core architecture involves a cross-β structure that is highly
stable due to the arrangement of backbone hydrogen bonding, which is
a property shared by all polypeptide sequences. Amyloid fibrils may in
fact be more thermodynamically stable than natively folded states, even
under physiological conditions. As the conversion from soluble protein
to fibrils requires intermolecular contacts, the thermodynamic stability
of fibrils is increased at higher protein concentrations [55].
Analysing the kinetics of amyloid formation has yielded a great deal
of information on the process of converting soluble natively folded
proteins to amyloid fibrils (Fig. 1). In the presence of a limited quantity
of monomeric soluble protein, the reaction typically follows a sigmoidal
curve over time, defined by a slow lag phase followed by a rapid growth
phase, and then reaching a plateau once the pool of monomers is de-
pleted. Soluble monomeric proteins initially polymerise through nu-
cleation mechanisms generating oligomers, species that then form
protofibrils, and finally mature fibrils. The rapid growth phase involves
elongation of the aggregate by the addition of free monomers to the
fibril ends, and also secondary processes, such as the fragmentation of
fibrils to increase the number of growing ends, or via secondary nu-
cleation in which a fibril acts as a catalytic site for free monomers to
aggregate. These mechanisms contribute to the generation of more
aggregates, demonstrating that amyloid growth is capable of rapid
proliferation following the initial nucleation process [55].
Like in other neurodegenerative disorders, including Alzheimer's
and Parkinson's disease, the presence of aggregates is linked to ALS
pathology; each condition is characterised by the progressive and gra-
dual spread of an aggregated signature protein deposited in inclusions
in a stereotypical pattern through the neuroaxis [57]. These observed
generic characteristics have led to the emergent concept of ‘prion-like
behaviour’ as a mechanism underlying the aggregation and spread of
misfolded proteins in these diseases, which is a conceptual framework
borrowed from prion diseases [56–58]. The mammalian cellular prion
protein, PrPc, is a glycosyl-phosphatidylinositol anchored membrane-
bound glycoprotein encoded by the PRNP gene that can misfold into the
β-sheet rich pathological conformer PrPSc. What makes the prion
M.A. Hanspal et al. BBA - Molecular Basis of Disease 1863 (2017) 2762–2771
2764
unique is not its capacity to self-propagate through induced misfolding
and amplification in an amyloidogenic manner, reflected by an in-
cubation period of several years followed by a rapid clinical presenta-
tion phase, but by its transmissibility between individuals and, ex-
ceptionally, across species [59]. Such infectivity appears to occur
without RNA or DNA driving replication, unlike conventional infectious
agents such as bacteria or viruses, with the term ‘protein only hy-
pothesis’ sometimes used to refer to the causative agent of prion dis-
eases [60]. To propagate pathology throughout the CNS, the patholo-
gical conformer is thought to leave an affected cell and to be taken up
by surrounding cells, where it induces the conversion (also known as
‘seeding’) of endogenous natively folded protein counterparts into the
pathological conformation, ultimately causing misfolding and ag-
gregation to spread [61].
Both mammalian and yeast prions share the ability to form amyloid
fibrils, but while the former appears to be pathogenic, the latter are
normally functional and can even be advantageous in yeast. Out of
20,000 human protein-encoding genes analysed, 240 genes have been
identified as containing sequences related to yeast prion-like domains,
which are typically enriched in polar, uncharged amino acids [62].
Thirty percent of these are RNA binding proteins, including TDP-43 and
FUS, indicating that these low complexity sequences are important for
function under normal physiological conditions [62]. The prion-like
domain, in particular of TDP-43, confers a high aggregation propensity
[16], which may explain why many proteins containing these se-
quences may misfold and aggregate in neurodegenerative diseases.
SOD1 does not contain a prion-like domain, but shares many attributes
with mammalian prions, including self-replication in vitro and transfer
of aggregates in culture [32].
Prion-like propagation is rapidly gaining popularity as an explana-
tion for the progressive intercellular spread of misfolded protein, but it
does not entirely explain how proteins that are expressed throughout
the nervous system during our life span can start to misfold and ag-
gregate in specific regions, before pathology disseminates to more
distant areas [63]. The ‘selective vulnerability’ hypothesis puts forward
the idea that certain neuronal populations within the CNS are more
susceptible to insults than others, and as these stresses accumulate over
time, they induce the misfolding and aggregation of endogenous pro-
tein in these cells. Stress signals are transmitted to other populations
through diffusible extracellular factors or directly through trans-sy-
naptic signaling, which causes aggregation in less susceptible popula-
tions [64]. It is very likely that these mechanisms operate in combi-
nation in neurodegenerative disease, making it imperative that we work
to fully characterise the process of cell-to-cell aggregate transfer and its
relevance to neurodegenerative disease.
Several subcellular mechanisms may contribute to cell-to-cell
transmission of aggregates, but the process broadly depends on four
events: 1) an aggregate passing across the membrane of the donor cell,
2) traversing the extracellular environment, 3) crossing the membrane
of the recipient cell and 4) interacting with endogenous natively folded
conformers and inducing misfolding [61,64]. The mammalian prion
overcomes the first two stages as it is exposed to the extracellular en-
vironment from its location on the plasma membrane, and is secreted
under normal physiological conditions. Most pathogenic misfolding
proteins, however, are normally cytosolic, or in the case of TDP-43,
shuttle between the nucleus and cytoplasm [64]. Several non-classical
routes of entry have been suggested, some of which depend on direct
contact between cells (tunneling nanotubes, transynaptic contacts), and
some of which are contact independent (exosomes, naked aggregates)
(Fig. 2) [65–67] (reviewed in [61]).
Cell-to-cell transfer of aggregates is less well-characterised in ALS
compared to other neurodegenerative disorders such as Alzheimer's or
Parkinson's diseases, but there remains a strong possibility that prion-
like mechanisms are relevant to the pathogenesis of the disease (re-
viewed in [68]). Sporadic ALS patients have significantly elevated le-
vels of either TDP-43 or SOD1 in their cerebrospinal fluid (CSF) com-
pared to age matched controls, especially at earlier stages of the
Fig. 1. Schematic representation of the kinetics of amyloid formation. Amyloid formation
is characterised by an initial lag phase in which monomeric species nucleate and form
oligomeric species followed by a growth phase of fibril formation, which occurs through
elongation and secondary events (fragmentation and/or secondary nucleation). A plateau
is reached when amyloid formation is in a steady state as free monomers (i.e. protein
molecules) are no longer available.
Fig. 2. Diagram showing cell-to-cell transfer. The pathological propagative species must
pass through the plasma membrane of the donor cell (1) to enter the extracellular en-
vironment (2), pass through the plasma membrane of the recipient cell (3) and then
induce the conversion of non-pathological protein into its pathological counterpart (4). In
this diagram, the propagative species is represented by an oligomeric species; however,
the exact structural nature of the transmissible species is not conclusively known.
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disease, which indicates that the proteins are released and circulate
around the body during the disease process [69–71]. Exosomes, small
endocytic vesicles that are secreted by most cell types into circulating
fluids including the CSF, are already implicated with the spreading of a
variety of pathological misfolded proteins [72]. Even cultured cells
release exosomes and other secreted factors directly into the culture
medium, allowing material to accumulate in the extracellular en-
vironment over time [73]. Collecting medium from cells overexpressing
a misfolding protein, here referred to as conditioned medium, and ap-
plying it to a fresh cell culture in order to observe internalisation,
provides an important strategy for modelling contact-independent in-
tercellular spread in vitro. Such experiments have been conducted in
neuron-like cell cultures using both TDP-43 and SOD1. SOD1 appears to
undergo cell-to-cell transfer via conditioned medium, and even propa-
gates over serial passages in culture [66]. In contrast, however, those
investigating this route for TDP-43 have not been able to demonstrate
conclusively that it undergoes cell-to-cell transfer in the same way
[27,74,75].
In the next section of this review, we describe the evidence of cell-
to-cell transfer via conditioned medium for a number of neurodegen-
erative diseases. We then describe the properties of SOD1 and TDP-43
and compare their respective abilities to participate in cell-to-cell
transfer via conditioned medium based on the evidence so far, with a
focus on experiments investigating neuron-to-neuron transfer in im-
mortalised cell lines. We go on to discuss how these differences in
routes of cell-to-cell transfer may implicate different mechanisms in-
volved in the spreading of pathology in ALS.
2. Conditioned medium as a route for cell-to-cell transfer
The experimental paradigm of conditioned medium is dependent on
a population of cells in culture that secrete factors into the extracellular
environment (known as a donor population). A population of cells
without prior exposure to the secreted material (the acceptor popula-
tion) is then cultured in the conditioned medium to observe whether or
not the material originating from the donor population can be inter-
nalised by the acceptor cells. Using conditioned medium provides a
simpler system to explore cell-to-cell transfer than in vivo models, as
well as providing much greater control over the experimental condi-
tions.
Conditioned medium experiments can be categorised according to
one of four strategies (Fig. 3):
1) The donor and acceptor cultures are separated by a porous mem-
brane or barrier to prevent cell-to-cell contact,
2) The conditioned medium is collected from donor cells and applied to
the acceptor culture,
3) Components, such as exosomes, of the conditioned medium are
isolated and applied to the acceptor culture,
4) Complementary protein assay models, which employ a biolumines-
cent complementary fragment reporter system, such as luciferase, to
label the protein of interest in order to report on its aggregation
state in conditioned medium. The protein of interest is labelled with
one of two complementary fragments. Bioluminescence only occurs
if the two complementary fragments are in close enough proximity
to fold into the full functional label, which is dependent on at least
two complementary labelled proteins associating with one another,
indicating the formation of dimers, oligomers or larger aggregates.
The conditioned medium is collected from donor cells co-expressing
the protein with each label and is applied to the acceptor culture.
3. Evidence of cell-to-cell transfer of misfolding proteins through
conditioned medium experiments
Cell models have used a variety of different mammalian prion
strains, in combination with immortalised and primary neuronal and
non-neuronal cell lines, to explore the mechanisms of prion release and
uptake between cells [59]. A strain is defined by a specific conforma-
tion that is adopted by the normal cellular PrPC prion during the con-
version process to the aberrant scrapie PrPSc prion, which is then
faithfully and stably propagated in a host [60]. This, in part, determines
the pathological and biophysical properties of a particular strain. Sev-
eral studies have demonstrated that mammalian prion strains can
propagate between neighbouring cells using conditioned medium, some
in association with exosomes, but this may depend on the properties of
the strain used as well as the cell type. For example, the use of neuron-
like Neuro-2A cells overexpressing the mouse adapted scrapie prion
strain 22 L shows cell-to-cell transfer via conditioned medium, but the
same cell line overexpressing another mouse adapted scrapie prion
strain (RML) shows no or little transfer through the same route [76–78]
Fig. 3. Different conditioned medium experimental proce-
dures. 1) A porous membrane barrier prevents direct contact
between the donor and acceptor cultures, allowing only se-
creted factors of a particular size in the medium to pass be-
tween the two compartments 2) Medium from the donor
culture is collected and a naïve acceptor culture is incubated
in the conditioned medium 3) Before applying the medium
from the donor culture to the acceptor culture, components of
the conditioned medium are extracted or concentrated 4) The
donor culture co-express protein labelled with one of two
complimentary fragments that luminesce when in close
proximity with one another, which is dependent on self-as-
sociation of at least two proteins labelled with one of each
fragment. Application of conditioned medium obtained from
the donor culture onto the acceptor culture will result in
bioluminescence in acceptor cells only if the luminescent
aggregate species are taken up by the acceptor culture.
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(for a full review of cell models of mammalian prion strain propagation,
see [79]). Building on experiments carried out on mammalian prion
strains in conditioned medium, researchers have been able to demon-
strate cell-to-cell transfer of many other aggregation-prone proteins
involved in neurodegenerative diseases using similar experimental
procedures, a variety of aggregate species and different immortalised
neuron-like cell lines (Table 1).
4. Conditioned medium experiments using SOD1 or TDP-43
4.1. Conditioned medium experiments using SOD1
Earlier experiments using pre-formed fluorescently labelled variant
SOD1H46R aggregates revealed that these aggregates could be en-
docytosed by Neuro 2A cells when exogenously applied to the culture
medium [45]. These aggregates were capable of converting in-
tracellular SOD1H46R in transfected Neuro 2A cells into puncta that
persisted in culture even after the exogenous aggregates had been de-
graded. Cell-to-cell transfer of different fluorescently labelled ag-
gregates was shown to occur between populations inoculated separately
before mixing, even when separated by a 0.4 μm filter membrane,
showing that cell-to-cell contact was not necessary for the transfer of
these aggregates [45]. Further experiments involving a full-length
variant SOD1 (SOD1G85R), a C-terminally truncated SOD1 variant
(SOD1G127X, containing the dominantly inherited G127insTGGG mu-
tation) and WT SOD1 have demonstrated that conditioned medium can
propagate aggregates between cells [66,88]. In addition, misfolded
SOD1G127X can interact with intracellular WT SOD1 in NSC-34 cells,
converting it to a misfolded conformation by the formation of non-
native SOD1 interchain disulphide bonds [88]. Moreover, over-
expression of WT SOD1 in cell culture induces misfolding of a propor-
tion of this intracellular SOD1, suggesting that a spontaneous mis-
folding event may trigger sALS through induced conversion of natively
folded SOD1 by a pathological conformer [88]. The discovery that WT
SOD1 is also involved in misfolding and aggregation is particularly
significant, as this implicates it as a common pathological mechanism
irrespective of whether ALS is sporadic or familial [44].
Several GFP labelled SOD1 variants (SODA4V, SODG93A and
SODG127X), as well as human WT SOD1-GFP, transiently overexpressed
in NSC-34 cells caused increases in cell death 72 h post-transfection
[66]. Western blot analysis and filter trap assays identified oligomeric
aggregates (larger than the 0.2 μm membrane pore size) present in the
culture medium, including those of WT SOD1, suggesting that dying
cells can release aggregates directly into the extracellular environment.
However, this cell line is also known to release exosomes, and in stably
transfected cells overexpressing different SOD1 variants, exosomes ex-
posed misfolded SOD1 onto the surface of the membrane, in contrast to
natively folded WT SOD1, which is normally localised in the lumen
[44,66,89].
Conditioned medium was collected from human embryonic kidney
cells, HEK293, transiently transfected with SOD1 (SODG85R, SODG127X
or WT SOD1) 48 h post-transfection, as these cells displayed resistance
to misfolded SOD1 toxicity [66]. Naïve recipient cells expressing en-
dogenous WT SOD1 were cultured in conditioned medium containing
variant or WT SOD1 to determine whether or not seeding could be
observed. Seeding was in fact serially propagated between cultures over
five passages, providing very strong evidence for the prion-like propa-
gation of misfolded SOD1 as a competent seed [66]. Together, this
shows that both pathways dependent and independent on exosomes are
involved in cell-to-cell transfer using conditioned medium. Exosome
independent SOD1 aggregates are taken up via macropinocytosis, a
form of non-selective endocytosis characterised by ruffling in the
plasma membrane, resulting in the engulfment of large fluid-phase
molecules into vesicles [90]. The exosome independent uptake of SOD1
involves a mechanism specific to SOD1 but is not aggregate specific, as
soluble SOD1 species are internalised with the same efficiency, sug-
gesting that this process is receptor mediated [89]. Experiments with a
microglial cell line have already shown that scavenger receptors par-
ticipate in selective uptake of SOD1 [91].
4.2. TDP-43 in conditioned medium experiments
The SOD1 serial propagation model was also used to investigate
whether or not there is a cross-seeding effect between TDP-43 and
SOD1 through conditioned medium [74]. The culture medium of
HEK293 cells transiently transfected with TDP-43 was collected after
48 h and centrifuged to remove cell debris, as with previous experi-
ments. WT TDP-43 and a variant lacking the nuclear localisation signal
(TDP-43ΔNLS), causing it to remain in the cytoplasm and undergo ag-
gregation, were used. This medium was then supplemented with 25%
fresh complete medium and applied to naïve cells for a 20 h incubation
period. Quantitative immunoprecipitation confirmed that 20–40% of
detectable endogenous WT SOD1 was misfolded in the lysate of cells
incubated with either WT TDP-43 or TDP-43ΔNLS. A 15–25 fold drop in
WT SOD1 occurred when endogenous SOD1 was knocked down in these
cells, excluding the possibility that misfolded WT SOD1 was transferred
from the original donor culture through the conditioned medium.
Using the same model, the question as to whether or not TDP-43
Table 1
Examples of misfolding proteins involved in neurodegenerative diseases that undergo cell-to-cell transfer in different conditioned medium experimental set ups. N.A., not applicable, N.C.,
not characterised.
Experimental set up Protein of interest Disease Transferring species Cell line
Membrane barrier Dipeptide repeat proteins from C9orf72
hexanucleotide repeat expansions
ALS N.C. NSC-34 [51]
SOD1 ALS N.C. Neuro 2 A [45]
Application onto acceptor
culture




Huntingtin (Q19 and Q103) Huntington's N.C. HEK donors and SH-SY5Y acceptors
[82]
α-Synuclein Parkinson's Monomers, oligomers and fibrils
[83]
High and low molecular weight
oligomers [84]
SH-SY5Y donors and COS-7 acceptors
[83]
Differentiated and undifferentiated SH-
SY5Y [84]
SOD1 ALS N.C [45]. Neuro 2 A [45]
TDP-43 ALS N.C. HEK293 [27,74]
Exosome isolation Yeast prion Sup35 (NM domain) N.A. Multimers [85]
N.C [86].
Neuro2A [85,86]
SOD1 ALS N.C. NSC-34 [66]
Complementary protein assay
model
Tau Alzheimer's N.C. HEK293T [87]
TDP-43 ALS Dimers, oligomers HEK293 [75]
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pathology was being propagated to recipient cells alongside the mis-
folded SOD1 was investigated. The over-expressed TDP-43ΔNLS ex-
hibited many of the pathological markers associated with TDP-43 in
ALS, including the clear generation of C-terminal truncated fragments
(CTFs) and hyperphosphorylated TDP-43 found exclusively in cyto-
plasmic puncta. These markers, however, were not found in en-
dogenously expressed TDP-43 in the naïve recipient cells incubated in
the conditioned medium during the same 20 h time period, suggesting
that the pathological TDP-43 could not confer its properties onto the
endogenous intracellular TDP-43 in the same manner.
Another recently published study described the application of exo-
genous seeding material, either the insoluble fraction of TDP-43 derived
from HEK293 cells transfected with WT FLAG-tagged TDP-43 (WT FL
TDP-43) or ALS patient tissue, via chemical transfection methods to
acceptor HEK293 cells over-expressing WT FL TDP-43 [27]. The re-
cipient cells showed increased levels of phosphorylated TDP-43 in re-
sponse to exposure to both the cell and patient derived seeds, with the
WT FL TDP-43 seeds showing a greater effect than the ALS patient in-
oculum, as demonstrated by immunocytochemistry and western blot-
ting. This effect was further increased after serial passaging, using a
subsequent set of recipient cells re-transfected with inoculum derived
from the first set of re-transfected cells. However, when conditioned
medium collected from cells re-transfected with the seeds was in-
cubated with naïve cells for 72 h, no cell-to-cell transfer was observed.
To date, there is only one reported cell model that demonstrates
TDP-43 transferring between cells via conditioned medium. This par-
ticular model uses a protein complementation technique based on a
two-part luciferase reporter system to quantify intracellular dimers and
oligomers, as determined by size exclusion chromatography [75]. TDP-
43 was fused to the N-terminal or C-terminal fragment of a luciferase
(TDP-L1 and TDP-L2 respectively) and bioluminescence can only occur
if these two constructs are both expressed and the proteins are inter-
acting. Thus, the bioluminescence detected as a consequence of the
interaction between the two luciferase fragments can be used to report
on the aggregation status of the intracellular TDP-43. HEK293 cells
were co-transfected with these constructs and the conditioned medium
was collected after 60 h. Bioluminescence was detected in the condi-
tioned medium, indicating that TDP-43 was present. When the condi-
tioned medium was applied to naïve non-transfected HEK293 acceptor
cells for 72 h, luciferase activity was detected in the acceptor cells even
after repeated washing, showing that they were able to internalise the
dimers or oligomers present in the medium. A major advantage of this
strategy compared to other seeding experiments involving TDP-43 is
that the TDP-43 is spontaneously internalised by recipient cells, rather
than relying on lipofection to introduce the seed, which is less phy-
siologically applicable to the disease process.
5. Issues to be resolved in conditioned medium experiments using
TDP-43
Considering the many similarities between SOD1 and TDP-43,
which both show some evidence of prion-like propagation in vitro, it is
surprising to find that one misfolded protein is so readily transmissible
through conditioned medium, while the other appears unable to par-
ticipate as efficiently. Differences in the properties of the two proteins,
as well as in the experimental parameters of the various spreading
models, may all contribute to explaining why cell-to-cell TDP-43
transfer has not been conclusively observed so far, with the exception of
the complementary protein assay model [75]. SOD1 and TDP-43 in-
clusions rarely co-localise in sALS, and there is experimental evidence
in cell models suggesting that SOD1 and TDP-43 are sequestered into
distinct inclusions through different pathways [92], which could mean
that these two proteins are involved in separate disease mechanisms.
More recent evidence, showing that both WT TDP-43 and TDP-43ΔNLS
can induce WT SOD1 aggregation in cell cultures via conditioned
medium instead implies that there is a mechanistic overlap between the
two proteins, and there may be other reasons why there is no clear
evidence for cell-to-cell transfer of TDP-43 using conditioned medium
[74].
A variety of explanations for the differences have been proposed,
including variations in the incubation periods, that the concentration of
secreted TDP-43 is too low for uptake or subsequent seeding inside
acceptor cells, the aggregates are not stable, or that TDP-43 transfer
may be exclusively dependent on cell-to-cell contact [27]. The SOD1
model for conditioned medium transfer incubated the donor culture in
medium for 48 h post-transfection before collecting, and incubated the
acceptor culture for a further 20 h [66]. Using the same experimental
set up, it was reported that TDP-43 did not undergo cell-to-cell transfer
under the same time frame [74]. In the WT FL TDP-43 model it was
unclear how long the donor culture was incubated before it was applied
to the acceptor cells; therefore, although the incubation period for the
acceptor culture was 72 h, the initial incubation period may not have
been sufficient for TDP-43 to accumulate in the medium [27]. The only
TDP-43 model that reports spreading via conditioned medium in-
cubated the donor culture for 60 h before applying this medium to
naïve cells for a further 72 h, so it may be that TDP-43 takes longer to
be released and taken up at appreciable concentrations to allow the
observation of internalisation of TDP-43 in acceptor cells [75].
Interestingly, in the studies that did not observe the transfer of TDP-
43 via conditioned medium, the levels of TDP-43 present within the
medium were not quantified, whereas these levels were confirmed in
the study involving the protein complementation-based model mon-
itored with bioluminescence [75]. Immunodetection techniques, in-
cluding immunoprecipitation, could be used to determine whether
TDP-43 is present at detectable levels. Even if TDP-43 is secreted by
donor cells, it may be that the levels are too low in the reported models
to be detected in recipient cells. Concentrating the medium, or isolating
exosomes as has been done using SOD1 conditioned medium, may
provide better conditions for spreading through this route. TDP-43
uptake has been reported in several studies, but apart from the model
using the protein complementation assay, most have relied on chemical
transfection methods to facilitate internalisation, which is less physio-
logically relevant [22,26,27,75]. On the other hand, it is possible that
the luciferase tags in the complementation assay cause perturbations to
the conformation or stability of putative TDP-43 oligomers, so that the
propagative species in this model may not be formed in the other sys-
tems.
It is also possible that TDP-43 only undergoes cell-to-cell transfer
through close contact between cells, but the fact that incubating WT
SOD1 expressing recipient HEK293 cells with conditioned medium
containing WT TDP-43, but not WT FUS, can induce SOD1 misfolding
suggests that TDP-43 has an effect without intercellular contacts [74].
Furthermore, TDP-43 is found at elevated levels in CSF from ALS pa-
tients, providing a route by which TDP-43 pathology can disseminate
over long distances within the CNS [70]. Different routes may have
different efficiencies, with direct contact facilitating greater TDP-43
transfer than conditioned medium, but they may operate together ra-
ther than exclusively. Two recent models were used to observe spon-
taneous cell-to-cell transfer of TDP-43, one using turboGFP tagged TDP-
43 variant G249A in NSC-34 culture, and the other employed SH-SY5Y
cells stably expressing HA tagged WT TDP-43 as the donor population
[93,94]. In both cases, transfer took place under co-culture conditions,
and crucially neither use transfection to induce the transfer. These
models may provide a good foundation for further exploring the con-
tribution of conditioned medium versus cell contact using TDP-43.
A significant hindrance to understanding fully the role of TDP-43 in
ALS has been a lack of structural information for the full-length protein
due to its high aggregation propensity. Recent studies, however, have
provided detailed structural insights into the individual domains of
TDP-43 at the atomic level using both X-ray crystallography and solu-
tion NMR techniques to demonstrate the folded nature of the N-term-
inal and RRM domains and an intrinsically disordered C-terminal
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region [95–99]. This information has paved the way for insights into
the structural dynamics of TDP-43 and also investigations of potential
intra- and inter-molecular contacts that are likely to be pivotal for
elucidating the structural nature of the aggregate species that are
formed as part of the disease process.
Furthermore, it is unclear which aggregated species are disease re-
levant, as there are conflicting reports regarding the importance of
amyloid fibrils in the disease process. Two studies have found
Thioflavin S positive TDP-43 inclusions in a small subset of post-
mortem patient tissue, and another has shown that a synthetic peptide
based on an aggregation-prone region of the C-terminus forms ThT
positive fibrils in vitro that are capable of seeding aggregation and show
neurotoxicity in cell cultures, suggesting that pathological TDP-43 has
amyloid-like properties [22,24,25,100]. In contrast, overexpression of
full-length and the C-terminal fragment of TDP-43 in purified E. coli
inclusion bodies results in the formation of amorphous aggregates,
which lack any signatures of amyloid, but which are also highly toxic
when present in the cytosol of cells [101]. Recently, there has been a
shift in favour of the idea that smaller oligomeric species, rather than
stable mature amyloid structures, are the main driver of neuro-
pathology in neurodegenerative diseases [102,103]. This, however,
poses additional challenges in determining which species are most re-
levant to the disease, as oligomers represent a very heterogeneous
subset of aggregates in terms of size and structure [104].
Another factor to consider is the possibility that the properties of
propagation and toxicity are not linked, meaning that species that are
capable of cell-to-cell transfer may differ from the neurotoxic con-
formers, as is the case with mammalian prions [105,106]. For example,
highly toxic species may reduce infectivity by causing neuronal cell
death during the early stages of amyloid formation, terminating the
process before the production of more infectious aggregates. Fibril ri-
gidity may also affect these properties, as more stable amyloid ag-
gregates are less likely to undergo fragmentation, generating fewer
‘seeds’ for further induced misfolding of monomers [55]. For two of the
studies, the ‘seed’ was derived from clinically confirmed ALS patient
tissue showing TDP-43 positive inclusions, but the aggregates present
have not been robustly characterised using biophysical techniques, and
there is scope for heterogeneity between and within patient samples
[27,107].
The complexities of understanding the underlying mechanisms of
the spread of disease in ALS and other neurodegenerative diseases, is of
paramount importance to allow the development of effective ther-
apeutic interventions. A number of robust techniques have been de-
veloped in recent years to tackle these questions, and it is clear that in
systems for which we are able to gain insight into the structural attri-
butes of the putative seeding aggregates, it is possible to begin to elu-
cidate the mechanisms of cell-to-cell transfer. It is therefore clear that it
is imperative to identify the disease-relevant aggregate species in the
case of TDP-43 associated ALS, in order to understand fully how pro-
pagation within the CNS takes place under disease conditions. Given
the recent focus of many groups on defining the structural attributes of
TDP-43 in both its physiological and pathological states, we believe it is
possible to gain a fuller understanding of the relevance of amyloid and
other aggregate species to the disease progression in ALS.
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